Related Experiment Video
Updated: May 1, 2026
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
CD28z CARs and armored CARs
Hollie J Pegram1, Jae H Park, Renier J Brentjens
1From the *Department of Medicine, †Center for Cell Engineering, and ‡Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Centre, New York, NY.
Abstract:
CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the clinic with very promising outcomes. However, limitations to CAR T cell therapy exist. These include lack of efficacy against some tumors, specific targeting of tumor cells without affecting normal tissue and retaining activity within the suppressive tumor microenvironment. Whereas promising clinical trials are in progress, preclinical development is focused on optimizing CAR design, to generate "armored CAR T cells," which are protected from the inhibitory tumor microenvironment. Studies investigating the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies, are aimed at improving the antitumor efficacy of CAR T cell therapy. Other strategies aimed at improving CAR T cell therapy include using dual CARs and chemokine receptors to more specifically target tumor cells. This review will describe the current clinical data and some novel armored CAR T cell approaches for improving antitumor efficacy therapy.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise but faces challenges. Armored CAR T cells are being developed to overcome tumor microenvironment limitations and improve treatment efficacy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- CD19-targeted chimeric antigen receptor (CAR) T cells demonstrate significant clinical promise.
- Current CAR T cell therapy faces limitations including efficacy, tumor specificity, and the suppressive tumor microenvironment.
Purpose of the Study:
- To review current clinical data on CAR T cell therapy.
- To explore novel "armored" CAR T cell strategies for enhancing antitumor efficacy.
Main Methods:
- Preclinical development focuses on optimizing CAR design for enhanced function.
- Strategies include "armored" CAR T cells, cytokine transgenes, combination therapies, dual CARs, and chemokine receptors.
Main Results:
- Ongoing clinical trials show promising outcomes for CAR T cell therapy.
- Preclinical research is actively developing methods to overcome existing limitations.
Conclusions:
- "Armored" CAR T cell approaches offer potential solutions to improve therapy effectiveness.
- Further research into novel CAR designs and combination strategies is crucial for advancing CAR T cell therapy.
